» Articles » PMID: 10833517

Developmental Stage-specific Biosynthesis of Glycosylphosphatidylinositol Anchors in Intraerythrocytic Plasmodium Falciparum and Its Inhibition in a Novel Manner by Mannosamine

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2000 Jun 2
PMID 10833517
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Glycosylphosphatidylinositols (GPIs) are the major glycoconjugates in intraerythrocytic stage Plasmodium falciparum. Several functional proteins including merozoite surface protein 1 are anchored to the cell surface by GPI modification, and GPIs are vital to the parasite. Here, we studied the developmental stage-specific biosynthesis of GPIs by intraerythrocytic P. falciparum. The parasite synthesizes GPIs exclusively during the maturation of early trophozoites to late trophozoites but not during the development of rings to early trophozoites or late trophozoites to schizonts and merozoites. Mannosamine, an inhibitor of GPI biosynthesis, inhibits the growth of the parasite specifically at the trophozoite stage, preventing further development to schizonts and causing death. Mannosamine has no effect on the development of either rings to early trophozoites or late trophozoites to schizonts and merozoites. The analysis of GPIs and proteins synthesized by the parasite in the presence of mannosamine demonstrates that the effect is because of the inhibition of GPI biosynthesis. The data also show that mannosamine inhibits GPI biosynthesis by interfering with the addition of mannose to an inositol-acylated GlcN-phosphatidylinositol (PI) intermediate, which is distinctively different from the pattern seen in other organisms. In other systems, mannosamine inhibits GPI biosynthesis by interfering with either the transfer of a mannose residue to the Manalpha1-6Manalpha1-4GlcN-PI intermediate or the formation of ManN-Man-GlcN-PI, an aberrant GPI intermediate, which cannot be a substrate for further addition of mannose. Thus, the parasite GPI biosynthetic pathway could be a specific target for antimalarial drug development.

Citing Articles

Glycosylation in malaria parasites: what do we know?.

Gowda D, Miller L Trends Parasitol. 2024; 40(2):131-146.

PMID: 38262838 PMC: 10923157. DOI: 10.1016/j.pt.2023.12.006.


Selection of an Aptamer against the Enzyme 1-deoxy-D-xylulose-5-phosphate Reductoisomerase from .

Roca C, Avalos-Padilla Y, Prieto-Simon B, Iglesias V, Ramirez M, Imperial S Pharmaceutics. 2022; 14(11).

PMID: 36432706 PMC: 9695703. DOI: 10.3390/pharmaceutics14112515.


Enzymatic and structural characterization of HAD5, an essential phosphomannomutase of malaria-causing parasites.

Frasse P, Miller J, Polino A, Soleimani E, Zhu J, Jakeman D J Biol Chem. 2022; 298(2):101550.

PMID: 34973333 PMC: 8808168. DOI: 10.1016/j.jbc.2021.101550.


Repurposing bioenergetic modulators against protozoan parasites responsible for tropical diseases.

Martinez-Florez A, Galizzi M, Izquierdo L, Bustamante J, Rodriguez A, Rodriguez F Int J Parasitol Drugs Drug Resist. 2020; 14:17-27.

PMID: 32829099 PMC: 7452664. DOI: 10.1016/j.ijpddr.2020.07.002.


Decoding the Role of Glycans in Malaria.

Gomes P, Feijo D, Morrot A, Freire-de-Lima C Front Microbiol. 2017; 8:1071.

PMID: 28649240 PMC: 5465260. DOI: 10.3389/fmicb.2017.01071.